Purdue Pharma Cuts More Than Half of U.S. Sales Staff Amid Opioid Crisis Post author:Sam Post published:February 12, 2018 Post category:BioPharma That announcement is a big change in the way Purdue has aggressively marketed OxyContin in the past. Source: BioSpace You Might Also Like Bristol-Myers Who? Why a Marriage Between Pfizer and Biogen Makes More Sense November 13, 2017 Otsuka Pharma Believes in Akebia, Commits Another $865 Million to Expand Anemia Deal April 25, 2017 Incyte Release: Combination Of Epacadostat Plus Keytruda (Pembrolizumab) Demonstrates Activity In Clinical Trial Of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) June 4, 2017
Incyte Release: Combination Of Epacadostat Plus Keytruda (Pembrolizumab) Demonstrates Activity In Clinical Trial Of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) June 4, 2017